/JCRRF
JCRRF Stock - JCR Pharmaceuticals Co., Ltd.
Healthcare|Drug Manufacturers - GeneralOTC
$4.75+0.00%
+$0.00 (+0.00%) • Jan 13
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.65
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $5.23
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for JCRRF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.70 – $4.80
TARGET (TP)$5.46
STOP LOSS$4.37
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.06
52W High$5.00
52W Low$3.78
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $33.07B | $42.87B | $34.34B | $51.08B | $30.09B |
| Gross Profit | $21.74B | $31.25B | $25.46B | $40.62B | $22.27B |
| Gross Margin | 65.7% | 72.9% | 74.1% | 79.5% | 74.0% |
| Operating Income | $-6,650,000,000 | $7.53B | $4.97B | $19.93B | $8.27B |
| Net Income | $-4,759,000,000 | $5.51B | $3.77B | $14.51B | $6.89B |
| Net Margin | -14.4% | 12.8% | 11.0% | 28.4% | 22.9% |
| EPS | $-38.43 | $44.13 | $30.34 | $117.26 | $55.80 |
Company Overview
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
JCRRFBeat Rate
42%
Last 19 quarters
Avg Surprise
+34.4%
EPS vs Estimate
Beats / Misses
8/11
Last 12 quarters
Latest EPS
$0.00
Q4 2025
EPS Surprise History
Q1 24
-121.1%
$-0.01vs$0.03
Q2 24
-83.5%
$0.02vs$0.11
Q3 24
-81.0%
$0.01vs$0.05
Q4 24
-152.4%
$-0.05vs$0.10
Q1 25
-92.0%
$0.01vs$0.07
Q2 25
+37.1%
$-0.23vs$-0.36
Q3 25
-202.3%
$-0.03vs$0.03
Q4 25
-99.4%
$0.00vs$0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Jan 28, 2026 | — | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.14 | $0.00 | -99.4% | ✗ MISS |
Q3 2025 | Jul 30, 2025 | $0.03 | $-0.03 | -202.3% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.36 | $-0.23 | +37.1% | ✓ BEAT |
Q1 2025 | Jan 31, 2025 | $0.07 | $0.01 | -92.0% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $0.10 | $-0.05 | -152.4% | ✗ MISS |
Q3 2024 | Jul 30, 2024 | $0.05 | $0.01 | -81.0% | ✗ MISS |
Q2 2024 | May 10, 2024 | $0.11 | $0.02 | -83.5% | ✗ MISS |
Q1 2024 | Jan 26, 2024 | $0.03 | $-0.01 | -121.1% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $0.09 | $0.19 | +124.4% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $0.05 | $0.09 | +69.7% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $0.05 | $0.01 | -76.3% | ✗ MISS |
Q1 2023 | Jan 31, 2023 | $0.00 | $0.16 | +3512.1% | ✓ BEAT |
Q4 2022 | Oct 26, 2022 | $-0.00 | $-0.02 | -3284.8% | ✗ MISS |
Q3 2022 | Jul 27, 2022 | $0.01 | $0.08 | +990.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $0.28 | $0.10 | -65.1% | ✗ MISS |
Q1 2022 | Jan 27, 2022 | $0.21 | $0.26 | +24.4% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $0.21 | $0.55 | +160.1% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $0.25 | $0.11 | -54.5% | ✗ MISS |
Q2 2021 | May 13, 2021 | $0.18 | $0.27 | +47.5% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about JCRRF
What is JCRRF's current stock price?
JCR Pharmaceuticals Co., Ltd. (JCRRF) is currently trading at $4.75 per share. The stock has moved +0.00% today.
What is the analyst price target for JCRRF?
No analyst price targets are currently available for this stock.
What sector is JCR Pharmaceuticals Co., Ltd. in?
JCR Pharmaceuticals Co., Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the OTC exchange.
What is JCRRF's market cap?
JCR Pharmaceuticals Co., Ltd. has a market capitalization of $0.58 billion, making it a small-cap company.
Does JCRRF pay dividends?
No, JCR Pharmaceuticals Co., Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGYTF
Allergy Therapeutics plc
$0.11
Mkt Cap: $0.5B
AVNBF
Avon Technologies Plc
$26.81
Mkt Cap: $0.8B
BJTRF
Beijing Tong Ren Tang Chinese Medicine Company Limited
$0.65
Mkt Cap: $0.5B
BOIRF
Boiron S.A.
$30.00
Mkt Cap: $0.5B
GLASF
Glass House Brands Inc.
$9.00
Mkt Cap: $0.7B
GSGTF
GenSight Biologics S.A.
$0.19
Mkt Cap: $0.0B
LBLTF
Lattice Biologics Ltd.
$0.00
Mkt Cap: $0.0B
MNFSF
ManifestSeven Holdings Corporation
$0.00
Mkt Cap: $0.0B
SOLTF
Nxera Pharma Co., Ltd.
$5.71
Mkt Cap: $0.5B
VRNOF
Verano Holdings Corp.
$1.35
Mkt Cap: $0.5B
Explore stocks similar to JCRRF for comparison